Cynata Therapeutics Ltd has released a press release.
September 2019 Quarterly Report
Filed with ASX ·
6ix hasn’t read this filing yet.
Cynata Therapeutics Limited on 6ix
Story so far
Earlier from Cynata Therapeutics
- Cynata & Sumitomo Withdraw from Acquisition Discussions
- CYP Advances Towards Osteoarthritis Phase 2 Clinical Trial
- Cynata Receives US$3 million Fujifilm License Fee
- Fujifilm Exercises License Option in GvHD
- Update on Discussions with Sumitomo and Fujifilm
Later from Cynata Therapeutics
- Notice of Allowance from CIPO for Patent Application
- Cynata Awarded Grant for Coronary Artery Disease Study
- CYP Files Application to Commence Phase 2 CLI Clinical Trial
- Cymerus MSCs Effective in Preclinical Model of Sepsis
- Cynata Receives $1.892m R&D Tax Incentive Refund
Follow Cynata Therapeutics into a list and get an email when it puts out news.
Follow Cynata Therapeutics